Updates on Liquid Biopsy for Advanced NSCLC: A Consensus Statement from the IASLC-Updates on Liquid Biopsy for Advanced NSCLC

Updates on Liquid Biopsy for Advanced NSCLC_ A Consensus Statement from the IASLC

Video Transcription

Video Summary

In this webinar, the speakers discussed the role of liquid biopsies in advanced non-small cell lung cancer (NSCLC) treatment. They presented three different cases and discussed the potential treatment options based on the patient's genomic profiles. In case one, the patient had advanced NSCLC with liver metastases. The speakers discussed the different treatment options, including systemic therapy, immunotherapy alone, chemo-immunotherapy, waiting for tissue testing results, or using a liquid biopsy and proceeding with systemic chemotherapy. The consensus was that it is important to follow the guidelines and wait for tissue testing results before starting therapy, if possible. In case two, the patient had an EGFR mutation and was treated with first-line EGFR TKI therapy. The speakers discussed the importance of using liquid biopsies for monitoring and detecting acquired resistance mutations. In case three, the patient had a KRAS G12C mutation and STK11 mutation. The speakers discussed the treatment options and the potential use of targeted therapy or immunotherapy based on the genomic profile. Overall, the speakers emphasized the importance of comprehensive genomic profiling and using liquid biopsies to guide treatment decisions in advanced NSCLC.

Keywords

liquid biopsies

advanced non-small cell lung cancer

genomic profiles

systemic therapy

immunotherapy

tissue testing results

EGFR mutation

acquired resistance mutations

KRAS G12C mutation

comprehensive genomic profiling